title: High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells.
abstract: To design an efficient procedure to expand high avidity melanoma reactive T cells and to perform immunotherapies, we compared conditions of peripheral blood lymphocyte (PBL) stimulation by Melan-A/MART-1 peptides. Avidity of induced CTLs was evaluated by measuring their lysis and cytokine secretion to peptide-pulsed transporter-associated protein-deficient cells and to melanoma cells. In side-by-side experiments, we show that melanoma cells, either allogeneic or autologous, induced the growth of high avidity Melan-A-reactive CTLs from all donors, whereas essentially low avidity T cells were induced by peptide-pulsed PBLs. We also show that at least two cytokines, interleukin-6 and interleukin-2, were required to promote the growth of high avidity CTLs. Once sorted by tetramer labeling or cloning, the specificity and reactivity to tumor cells of peptide-specific T cells induced by allogeneic melanoma cells were confirmed. We then describe a relatively simple and efficient procedure that allowed us to obtain systematically high amounts (in the range of billion) of high avidity Melan-A/ MART-1-specific T cells from the PBLs of HLA-A2 melanoma patients and healthy donors in 3 months. Because this antigen is expressed by most melanoma tumors, this procedure should be useful for checking the efficiency of adoptive immunotherapy of melanoma tumors and using functionally well-defined Melan-A/MART-1-specific CTLs in a large group of patients.
authors.affiliation: Institut de Biologie, INSERM U463, Nantes, France.
authors.forename: N
authors.initials: N
authors.lastname: Gervois
authors.forename: N
authors.initials: N
authors.lastname: Labarriere
authors.forename: S
authors.initials: S
authors.lastname: Le Guiner
authors.forename: M C
authors.initials: MC
authors.lastname: Pandolfino
authors.forename: J F
authors.initials: JF
authors.lastname: Fonteneau
authors.forename: Y
authors.initials: Y
authors.lastname: Guilloux
authors.forename: E
authors.initials: E
authors.lastname: Diez
authors.forename: B
authors.initials: B
authors.lastname: Dreno
authors.forename: F
authors.initials: F
authors.lastname: Jotereau
mesh_terms: D000595:Amino Acid Sequence; D000951:Antigens, Neoplasm; D002455:Cell Division / Q000187:drug effects / Q000276:immunology; D002999:Clone Cells; D003602:Cytotoxicity, Immunologic; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D006801:Humans; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D058965:MART-1 Antigen; D008545:Melanoma / Q000276:immunology* / Q000473:pathology; D009363:Neoplasm Proteins / Q000276:immunology* / Q000494:pharmacology; D009842:Oligopeptides / Q000276:immunology / Q000494:pharmacology; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D014407:Tumor Cells, Cultured / Q000166:cytology / Q000187:drug effects / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; D058965:MART-1 Antigen; C548667:MLANA protein, human; D009363:Neoplasm Proteins; D009842:Oligopeptides